Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: Implications for schizophrenia

Neuroscience

Volumn 107, Issue 4, 2001, Pages 535-550

  Wang, C ^a,b   McInnis, J ^a   Ross Sanchez, M ^a   Shinnick Gallagher, P ^a,b   Wiley, J L ^c   Johnson, K M ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Delayed spatial alternation; Frontal cortex; N methyl D aspartate receptor; Olanzapine; Prepulse inhibition

Indexed keywords

DIZOCILPINE; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NUCLEAR FACTOR; OLANZAPINE; PHENCYCLIDINE; PROTEIN BAX; PROTEIN BCL X; PROTEIN SUBUNIT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASSAY; BEHAVIOR; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; GEL; IMMUNOBLOTTING; LOCOMOTION; NERVE DEGENERATION; NONHUMAN; OLFACTORY CORTEX; PERINATAL PERIOD; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STARTLE REFLEX; WEANING;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BEHAVIOR, ANIMAL; BENZODIAZEPINES; FEMALE; FRONTAL LOBE; GENE EXPRESSION; HALLUCINOGENS; MOTOR ACTIVITY; NERVE DEGENERATION; NEURONS; NF-KAPPA B; PHENCYCLIDINE; PIRENZEPINE; PREGNANCY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 0035965675     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(01)00384-0     Document Type: Article

References (95)

1. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine
2. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurons by N-methyl-D-aspartate
3. Clozapine and haloperidol modulate N-methyl-D-aspartate and non-N-methyl-D-aspartate-mediated neurotransmission in rat prefrontal cortical neurons in vitro
4. 2A receptor antagonists and potential antipsychotic drug, facilitates N-methyl-D-aspartate-mediated neurotransmission in the rat prefrontal cortical neurons in vitro
5. Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine
6. Cloning and analysis of the 5′ flanking sequence of the rat N-methyl-D-aspartate receptor 1 (NMDAR1) gene
7. Functional analysis of the proximal 5′-flanking region of the N-methyl-D-aspartate receptor subunit gene (NMDAR1)
8. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine
9. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating deficits of the startle response
10. Disruption of prepulse inhibition and increases in locomotor activity by competitive N-methyl-D-aspartate receptor antagonists in rats
11. Stress-induced increase in vasopressin and corticotrophin-releasing factor expression in hypophysiotrophic paraventricular neurons
12. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
13. Altered glutamatergic and GABAergic mechanism in the cingulate cortex of the schizophrenic brain
14. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients
15. Gating and habituation of the startle reflex in schizophrenic patients
16. Radioreceptor binding profile of the atypical antipsychotic olanzapine
17. Olanzapine: A basic science update
18. Is phencyclidine (PCP) abuse associated with organic mental impairment?
19. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease
20. Neonatal medial prefrontal lesions and recovery of spatial delayed alternation in the rat: Effects of delay interval
21. Acute and chronic phencyclidine effects on locomotor activity, stereotypy and ataxia in rats
22. Bcl-2 family: Regulators of cell death
23. Recovery of neuropsychological functions during reduction in use of phencyclidine
24. Bax-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons
25. A 'glutamatergic hypothesis' of schizophrenia
26. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei
27. Olanzapine and fluperlapine mimic clozapine in preventing MK-802 neurotoxicity
28. Effects of neonatal dopamine depletion on spatial ability during ontogeny
29. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist (+)-MK801 (dizocilpine maleate): A light and electron microscopic evaluation of the rat retrosplenial cortex
30. Medial prefrontal cortex lesions and spatial delayed alternation in the developing rat: Recovery or sparing?
31. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
32. Intracellular oxidation/reduction status in the regulation of transcription factors NF-κB and AP-1
33. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice
34. The physiological approach: Functional architecture of working memory and disordered cognition in schizophrenia
35. Functional and anatomical aspects of prefrontal pathology in schizophrenia
36. Cortical abnormalities in schizophrenia identified by structural magnetic resonance imaging
37. Differential ontogeny of working memory and reference memory in the rat
38. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation
39. Augmentation of locomotor activity by chronic phencyclidine is associated with an increase in striatal NMDA receptor function and an upregulation of the NR1 receptor subunit
40. Single photon emission computerized tomography in phencyclidine and related drug abuse
41. Chronic ethanol treatment produces a sensitive upregulation of the NMDA receptor subunit gene expression in mammalian cultured cortical neurons
42. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain
43. Recent advances in the phencyclidine model of schizophrenia
44. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term phencyclidine administration
45. Chronic phencyclidine induces behavioral sensitization and apoptotic cell death in the olfactory and piriform cortex
46. The effect of ketamine on the acoustic startle response
47. Failure of haloperidol to block the effects of phencyclidine and dizolcipine on prepulse inhibition of startle
48. Risperidone prevents the development of supersensitivity, but not tolerance, to phencyclidine in rats treated with subacute phencyclidine
49. Ketamine activates psychosis and alters limbic blood flow in schizophrenia
50. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia
51. Intracellular modulation of NMDA receptor function by antipsychotic drugs
52. Development of the prefrontal cortex during adolescence: Insights into vulnerable neural circuits in schizophrenia
53. Phencyclidine: An Update
54. Study of a new psychotropic drug - Sernyl
55. Intrastriatal dopamine injection induces apoptosis through oxidation-involved activation of transcription factors AP-1 and NF-κB in rats
56. Nerve growth factor-dependent activation of NF-κB contributes to survival of sympathetic neurons
57. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat
58. Tumor supressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
59. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
60. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
61. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia
62. Heteromeric NMDA receptors: Molecular and functional distinction of subtypes
63. A neurodevelopmental approach to the classification of schizophrenia
64. Glutamate receptor dysfunction and schizophrenia
65. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs
66. NMDA antagonist neurotoxicity: Mechanism and prevention
67. NF-κB: A crucial transcription factor for glial and neuronal cell function
68. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B
69. Structural brain imaging in schizophrenia: A selective review
70. Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration
71. Chronic treatment with haloperidol diminishes the phencyclidine-induced sensorimotor gating deficit in rats
72. Schizophrenia: A neuro-developmental perspective
73. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol
74. Apoptotic cell death induced by optic nerve lesion in the neonatal rat
75. Interactions of phencyclidine receptor agonist MK-801 with the dopamineregic system: Regional studies in the rat
76. Subchronic administration of clozapine, but not haloperidol or metoclopramide, decreases dopamine D2 receptor messenger RNA levels in the nucleus accumbens and caudate-putamen in rats
77. MK801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulated and retrosplenial cortex
78. The effects of haloperidol and clozapine on PCP- and amphetamine-induced suppression of social behavior in the rat
79. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NF-κB activation in primary hippocampal neurons
80. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: Implications for antipsychotic drug treatment
81. Induction of tumour-suppressor phosphoprotein p53 in the apoptosis of cultured rat cerebellar neurones triggered by excitatory amino acids
82. Hydrogen peroxide induces nuclear translocation of p53 and apoptosis in cells of oligodendroglia origin
83. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: Modulation by dopamine
84. 18F]fluorodeoxyglucose
85. Mechanisms of N-methyl-D-aspartate-induced apoptosis in phencyclidine-treated cultured forebrain neurons
86. Chronic phencyclidine increases NMDA receptor NR1 subunit mRNA in rat forebrain
87. Facilitation of NMDA transmission by olanzapine
88. Implications of normal development for the pathogenesis of schizophrenia
89. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia: I. Regional cerebral blood flow evidence
90. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants
91. Bax involvement in p53-mediated neuronal cell death
92. Phencyclidine-induced behavioral sensitization
93. The in vivo effects of olanzapine and other antipsychotic agent receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors
94. MK-801 induces apoptotic neuronal death in the rat retrosplenial cortex: Prevention by cycloheximide and R(-)-2-hexyl-N-methylpropargylamine